NCT06109181View on ClinicalTrials.gov

Gene Therapy for ACM Due to a PKP2 Pathogenic Variant

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2027

Conditions
Arrhythmogenic CardiomyopathyPKP2-ACMPKP2-ARVC
Interventions
GENETIC

LX2020

LX2020 is an adeno-associated viral vector encoding the human Plakophilin-2 (PKP2) gene (AAVrh.10hPKP2)

Trial Locations (5)

14642

RECRUITING

University of Rochester, Rochester

21287

RECRUITING

Johns Hopkins University, Baltimore

29425

RECRUITING

Medical University of South Carolina, Charleston

48109

RECRUITING

University of Michigan, Ann Arbor

94305

RECRUITING

Stanford University, Stanford

Sponsors

Lead Sponsor

Lexeo Therapeutics
All Listed Sponsors
lead

Lexeo Therapeutics

INDUSTRY